{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:39:49Z","timestamp":1781188789253,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"crossref","award":["6-2022-0093"],"award-info":[{"award-number":["6-2022-0093"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Allogeneic hematopoietic stem cell transplantation remains a curative option for acute leukemia. While an adequate CD34<jats:sup>+<\/jats:sup> cell dose is essential for engraftment, the optimal upper threshold in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed 81 patients with acute leukemia who underwent haplo-PBSCT with reduced-intensity conditioning between 2010 and 2020. Patients were stratified by CD34<jats:sup>+<\/jats:sup> cell dose (&lt;\u20098\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg vs.\u2009\u2265\u20098\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg). Clinical outcomes, including overall survival (OS), non-relapse mortality (NRM), graft failure, and graft-versus-host disease (GVHD) incidence, were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A higher CD34<jats:sup>+<\/jats:sup> cell dose was associated with inferior OS (<jats:italic>P<\/jats:italic>\u2009=\u20090.022) and increased NRM (<jats:italic>P<\/jats:italic>\u2009=\u20090.002), despite similar rates of graft failure and acute GVHD. Chronic GVHD was more frequent in the higher dose group, though the difference was not statistically significant. Multivariate Cox analysis confirmed a high CD34<jats:sup>+<\/jats:sup> cell dose as an independent predictor of poor OS (HR 2.054, <jats:italic>P<\/jats:italic>\u2009=\u20090.031).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings suggest that excessively high doses may adversely affect survival by increasing transplant-related toxicity. Graft cell dose should be carefully balanced to optimize outcomes in haplo-PBSCT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s44313-025-00091-5","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:34:12Z","timestamp":1754555652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia"],"prefix":"10.1007","volume":"60","author":[{"given":"Haerim","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Kook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-0921","authenticated-orcid":false,"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"91_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/35077251","volume":"411","author":"FR Appelbaum","year":"2001","unstructured":"Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385\u20139.","journal-title":"Nature"},{"key":"91_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813\u201326.","journal-title":"N Engl J Med"},{"key":"91_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","volume":"36","author":"A Gratwohl","year":"2005","unstructured":"Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;36:757\u201369.","journal-title":"Bone Marrow Transplant"},{"key":"91_CR4","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"91_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood.V85.6.1659.bloodjournal8561659","volume":"85","author":"M K\u00f6rbling","year":"1995","unstructured":"K\u00f6rbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995;85:1659\u201365.","journal-title":"Blood"},{"key":"91_CR6","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1182\/blood-2009-03-208355","volume":"114","author":"MA Pulsipher","year":"2009","unstructured":"Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009;114:2606\u201316.","journal-title":"Blood"},{"key":"91_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/sj.leu.2402909","volume":"17","author":"M Mohty","year":"2003","unstructured":"Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia. 2003;17:869\u201375.","journal-title":"Leukemia"},{"key":"91_CR8","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.25826","volume":"95","author":"E Maffini","year":"2020","unstructured":"Maffini E, Labopin M, Blaise D, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2020;95:892\u20139.","journal-title":"Am J Hematol"},{"key":"91_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ejh.13332","volume":"104","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Atenafu EG, Bautista MR, et al. Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. Eur J Haematol. 2020;104:36\u201345.","journal-title":"Eur J Haematol"},{"key":"91_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/bmt.2014.94","volume":"49","author":"K Maie","year":"2014","unstructured":"Maie K, Fuji S, Tajima K, et al. A higher number of infused CD34+ cells has a positive impact on the clinical outcome after related PBSC transplantation. Bone Marrow Transplant. 2014;49:1113\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"91_CR11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/bmt.2012.75","volume":"47","author":"N Dh\u00e9din","year":"2012","unstructured":"Dh\u00e9din N, Pr\u00e9bet T, De Latour RP, et al. Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transplant. 2012;47:1564\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"91_CR12","doi-asserted-by":"publisher","first-page":"181.e1","DOI":"10.1016\/j.jtct.2022.12.005","volume":"29","author":"A Pedraza","year":"2023","unstructured":"Pedraza A, Salas MQ, Rodr\u00edguez-Lobato LG, et al. Effect of CD34(+) cell dose on the outcomes of allogeneic stem cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2023;29:181.e1-.e10.","journal-title":"Transplant Cell Ther"},{"key":"91_CR13","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/j.jtct.2025.01.397","volume":"31","author":"N Harada","year":"2025","unstructured":"Harada N, Okamura H, Kanda J, et al. Evaluation of the prognostic impact of infused CD34 positive cell dose in haplo-peripheral blood stem cell transplantation with post-transplantation cyclophosphamide using a restricted cubic spline curve. Transplant Cell Ther. 2025;31:S262.","journal-title":"Transplant Cell Ther"},{"key":"91_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"91_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.14","volume":"1","author":"B Mohty","year":"2011","unstructured":"Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J. 2011;1: e16.","journal-title":"Blood Cancer J"},{"key":"91_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2991\/chi.d.200221.001","volume":"2","author":"M Remberger","year":"2020","unstructured":"Remberger M, Gr\u00f8nvold B, Ali M, et al. The CD34(+) cell dose matters in hematopoietic stem cell transplantation with peripheral blood stem cells from sibling donors. Clin Hematol Int. 2020;2:74\u201381.","journal-title":"Clin Hematol Int"},{"key":"91_CR17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/bmt.2014.105","volume":"49","author":"A Xhaard","year":"2014","unstructured":"Xhaard A, Moins-Teisserenc H, Busson M, et al. Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:1089\u201392.","journal-title":"Bone Marrow Transplant"},{"key":"91_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23:211\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"91_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1046\/j.1365-2141.2000.01838.x","volume":"108","author":"E Bah\u00e7eci","year":"2000","unstructured":"Bah\u00e7eci E, Read EJ, Leitman S, et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol. 2000;108:408\u201314.","journal-title":"Br J Haematol"},{"key":"91_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbmt.2008.02.005","volume":"14","author":"R Nakamura","year":"2008","unstructured":"Nakamura R, Auayporn N, Smith DD, et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant. 2008;14:449\u201357.","journal-title":"Biol Blood Marrow Transplant"},{"key":"91_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jtct.2021.11.004","volume":"28","author":"TD Gauntner","year":"2022","unstructured":"Gauntner TD, Brunstein CG, Cao Q, et al. Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. Transplant Cell Ther. 2022;28:88\u201395.","journal-title":"Transplant Cell Ther"},{"key":"91_CR22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Swoboda R, et al. Young (<35 years) haploidentical versus old (\u226535 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation. Bone Marrow Transplant. 2024;59:1552\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"91_CR23","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1007\/s00277-024-05848-z","volume":"103","author":"P Zieli\u0144ska","year":"2024","unstructured":"Zieli\u0144ska P, Wieczorkiewicz-Kabut A, Bia\u0142as K, et al. Donor\u2019s age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience. Ann Hematol. 2024;103:3095\u2013104.","journal-title":"Ann Hematol"},{"key":"91_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00277-021-04399-x","volume":"100","author":"F Gao","year":"2021","unstructured":"Gao F, Zhang J, Hu J, Lin L, Xu Y. Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis. Ann Hematol. 2021;100:529\u201340.","journal-title":"Ann Hematol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00091-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00091-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:24:57Z","timestamp":1757370297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00091-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00091-5","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Severance Hospital, Seoul, Republic of Korea (IRB No. 4\u20132010-0669), and was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}